

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:	
Belantamab Mafodotin [Blenrep]	<5
Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	0
Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	0
Bortezomib [Velcade] ± Dexamethasone	0
Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)	<5
Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
Carfilzomib [Kyprolis] + Dexamethasone	0
Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	6
Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	8
Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	8
Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	23
Daratumumab [Darzalex] monotherapy	<5
Elranatamab	0
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	<5
Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)	<5
Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)	<5

Lenalidomide [Revlimid] + Dexamethasone	17
Lenalidomide [Revlimid] monotherapy	25
Panobinostat + Bortezomib + Dexamethasone	0
Pomalidomide [Imnovid] + Dexamethasone	0
Selinexor + Bortezomib [Velcade] + Dexamethasone	<5
Selinexor + Dexamethasone	<5
Talquetamab	0
Teclistamab [Tecvayli]	0

Any other systemic anti-cancer therapy [please specify]

C-Thal-dex attenuated	<5
RCD (lenalidomide, cyclophosphamide + dexamethasone)	<5
Zanubrutinib	<5

Q3 In the last 6 months, how many patients have been initiated* on the following regimens?

Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
Carfilzomib [Kyprolis] + Dexamethasone	0
Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	0
Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	<5
Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd)	0

Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	<5
Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	<5
Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	<5
Lenalidomide [Revlimid] monotherapy	<5
Lenalidomide [Revlimid] + Dexamethasone	<5
Selinexor + Bortezomib [Velcade] + Dexamethasone	<5
Selinexor + Dexamethasone	0
Any other systemic anti-cancer therapy [please specify]	0

Q4. In the last 6 months, how many patients have received the following second-line treatment?

- Lenalidomide [Revlimid] + Dexamethasone 13